Technical Analysis for ALNA - Allena Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 4.73 -1.87% -0.09
ALNA closed down 1.87 percent on Thursday, July 18, 2019, on approximately normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Earnings due: Jul 25

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ALNA trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
Down 3 Days in a Row Weakness 0.00%
50 DMA Support Bullish -1.87%
Narrow Range Bar Range Contraction -1.87%
Narrow Range Bar Range Contraction -3.47%
NR7 Range Contraction -3.47%
NR7-2 Range Contraction -3.47%
50 DMA Support Bullish -4.83%
NR7 Range Contraction -4.83%

Older signals for ALNA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Allena Pharmaceuticals, Inc. is a United States-based specialty biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones. ALLN-177 is an orally administered, recombinant oxalate-degrading enzyme. ALLN-177 targets oxalate in the gastrointestinal (GI) tract to reduce the burden of both dietary and endogenously produced oxalate. ALLN-177 has the potential to decrease the oxalate available systemically for deposition as calcium oxalate crystals or stones in the kidneys, as well as to reduce the incidence of calcium oxalate related complications. Its technological approach enables the design and development of oral protein therapies that remain in the GI tract.
Medicine Biopharmaceutical Medical Specialties Organ Systems Kidney Diseases Anticoagulants Hyperoxaluria
Is ALNA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.38
52 Week Low 3.92
Average Volume 163,476
200-Day Moving Average 6.9667
50-Day Moving Average 4.7912
20-Day Moving Average 4.7365
10-Day Moving Average 4.932
Average True Range 0.4163
ADX 21.52
+DI 25.3552
-DI 20.4541
Chandelier Exit (Long, 3 ATRs ) 4.4911
Chandelier Exit (Short, 3 ATRs ) 5.2489
Upper Bollinger Band 5.3534
Lower Bollinger Band 4.1196
Percent B (%b) 0.49
BandWidth 26.04877
MACD Line 0.0306
MACD Signal Line 0.0096
MACD Histogram 0.021
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.27
Resistance 3 (R3) 5.25 5.06 5.18
Resistance 2 (R2) 5.06 4.92 5.07 5.15
Resistance 1 (R1) 4.89 4.83 4.80 4.91 5.12
Pivot Point 4.70 4.70 4.65 4.71 4.70
Support 1 (S1) 4.53 4.56 4.44 4.55 4.34
Support 2 (S2) 4.34 4.47 4.35 4.31
Support 3 (S3) 4.17 4.34 4.28
Support 4 (S4) 4.19